

Vittorio Pengo

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8169476/vittorio-pengo-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

378
papers

17,491
citations

60
h-index

124
g-index

410
ext. papers

20,431
ext. citations

7
avg, IF

6.28
L-index

#	Paper	IF	Citations
378	Gender Related Differences in Gastrointestinal Bleeding With Oral Anticoagulation in Atrial Fibrillation.. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2022 , 27, 10742484211054609	2.6	1
377	Rationale and design of a study on D-dimer use to stratify patients after a first unprovoked venous thromboembolism for their risk of recurrence: extended low-dose Apixaban given only to patients with positive D-dimer results 2022 , 1, 38-44		
376	Prevalence of aPhosphatidylserine/prothrombin antibodies and association with antiphospholipid antibody profiles in patients with antiphospholipid syndrome: A systematic review and meta-analysis.. <i>Thrombosis Research</i> , 2022 , 214, 106-114	8.2	2
375	Do women with venous thromboembolism bleed more than men during anticoagulation? Data from the real-life, prospective START-Register.. <i>Therapeutic Advances in Drug Safety</i> , 2021 , 12, 20420986211062965	3.5	1
374	Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository. <i>Advances in Rheumatology</i> , 2021 , 61, 64	3	
373	Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. <i>Arthritis Care and Research</i> , 2021 , 73, 1490-1504	4.7	13
372	Design and rationale of a randomized, placebo-controlled trial on the efficacy and safety of sulodexide for extended treatment in elderly patients after a first venous thromboembolism. <i>Internal and Emergency Medicine</i> , 2021 , 16, 359-368	3.7	2
371	Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry. <i>Internal and Emergency Medicine</i> , 2021 , 16, 379-387	3.7	13
370	Insight into the hypercoagulable state of high-risk thrombotic APS patients: Contribution of a α GPI and aPS/PT antibodies. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 805-813	15.4	1
369	Peripheral arterial disease has a strong impact on cardiovascular outcome in patients with acute coronary syndromes: from the START Antiplatelet registry. <i>International Journal of Cardiology</i> , 2021 , 327, 176-182	3.2	5
368	Arterial thrombosis in antiphospholipid syndrome (APS): Clinical approach and treatment. A systematic review. <i>Blood Reviews</i> , 2021 , 48, 100788	11.1	2
367	Reduction in all-cause mortality in COVID-19 patients on chronic oral anticoagulation: A population-based propensity score matched study. <i>International Journal of Cardiology</i> , 2021 , 329, 266-269	3.2	18
366	Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 531-535	15.4	11
365	General population screening for atrial fibrillation with an automated rhythm-detection blood pressure device. <i>International Journal of Cardiology</i> , 2021 , 322, 265-270	3.2	1
364	Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository. <i>Journal of Rheumatology</i> , 2021 , 48, 541-547	4.1	4
363	Sex-based difference in anticoagulated patients with mechanical prosthetic heart valves and long-term mortality risk. <i>International Journal of Clinical Practice</i> , 2021 , 75, e14064	2.9	1
362	Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome. <i>Internal and Emergency Medicine</i> , 2021 , 16, 1583-1591	3.7	5

361	MiRNA 126 as a New Predictor Biomarker in Venous Thromboembolism of Persistent Residual Vein Obstruction: A Review of the Literature Plus a Pilot Study. <i>Seminars in Thrombosis and Hemostasis</i> , 2021 , 47, 982-991	5.3	1
360	Anti-phosphatidyl-serine/prothrombin antibodies (aPS/PT) in isolated lupus anticoagulant (LA): is their presence linked to dual test positivity?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021 , 59, 1950-1953	5.9	2
359	A Novel ELISA Assay for the Detection of Anti-Prothrombin Antibodies in Antiphospholipid Syndrome Patients at High Risk of Thrombosis. <i>Frontiers in Immunology</i> , 2021 , 12, 741589	8.4	1
358	Questions and Answers on Practical Thrombotic Issues in SARS-CoV-2 Infection: A Guidance Document from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology. <i>American Journal of Cardiovascular Drugs</i> , 2020 , 20, 559-570	4	5
357	Death rates and causes in anticoagulated atrial fibrillation patients: a population-based study. <i>Journal of Cardiovascular Medicine</i> , 2020 , 21, 415-419	1.9	4
356	Additional laboratory tests to improve on the diagnosis of antiphospholipid syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 1846-1848	15.4	11
355	The J-elongated conformation of Eglycoprotein I predominates in solution: implications for our understanding of antiphospholipid syndrome. <i>Journal of Biological Chemistry</i> , 2020 , 295, 10794-10806	5.4	11
354	Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs. <i>European Journal of Internal Medicine</i> , 2020 , 80, 73-77	3.9	3
353	Prothrombin Is Responsible for the Lupus Cofactor Phenomenon in a Patient with Lupus Anticoagulant/Hypoprothrombinemia Syndrome. <i>TH Open</i> , 2020 , 4, e40-e44	2.7	2
352	Benefit of dual antithrombotic therapy with direct oral anticoagulants in patients with atrial fibrillation undergoing percutaneous coronary intervention: a systematic review and metaanalysis of randomized clinical trials. <i>Internal and Emergency Medicine</i> , 2020 , 15, 1093-1104	3.7	2
351	Tetra positive thrombotic antiphospholipid syndrome: Major contribution of anti-phosphatidyl-serine/prothrombin antibodies to lupus anticoagulant activity. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 1124-1132	15.4	24
350	DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban- and rivaroxaban-treated patients from the START-Register. <i>International Journal of Laboratory Hematology</i> , 2020 , 42, 214-222	2.5	6
349	Antibody profiles comprising anti phosphatidylserine/prothrombin differently affect thrombin generation and protein C resistance in antiphospholipid antibody carriers. <i>Clinica Chimica Acta</i> , 2020 , 510, 796-801	6.2	4
348	D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study. <i>Internal and Emergency Medicine</i> , 2020 , 15, 453-462	3.7	7
347	Optimal Medical Therapy on Top of Dual-Antiplatelet Therapy: 1-Year Clinical Outcome in Patients With Acute Coronary Syndrome: The START Antiplatelet Registry. <i>Angiology</i> , 2020 , 71, 235-241	2.1	2
346	Characteristics of Antiphospholipid Antibody Positive Patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking. <i>Arthritis Care and Research</i> , 2020 ,	4.7	13
345	Bleeding and thrombotic complications during treatment with direct oral anticoagulants or vitamin K antagonists in venous thromboembolic patients included in the prospective, observational START2-register. <i>BMJ Open</i> , 2020 , 10, e040449	3	5
344	Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. <i>Lupus</i> , 2020 , 961203320940776	2.6	12

343	Oral anticoagulants in thrombotic antiphospholipid syndrome: Leave the old road for a new trail?. <i>European Journal of Internal Medicine</i> , 2020 , 79, 29-30	3.9	0
342	Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation.	15.4	57
341	Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 2126-2137	15.4	30
340	Additional laboratory tests to improve on the diagnosis of antiphospholipid syndrome: Response from Pengo. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 3118-3119	15.4	3
339	Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry). <i>American Journal of Cardiology</i> , 2019 , 124, 1662-1668	3	15
338	Patients with isolated pulmonary embolism in comparison to those with deep venous thrombosis. Differences in characteristics and clinical evolution. <i>European Journal of Internal Medicine</i> , 2019 , 69, 64-70	2.9	21
337	The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis. <i>Thrombosis Research</i> , 2019 , 175, 32-36	8.2	12
336	Balloon Pulmonary Angioplasty in Patients With Chronic Thromboembolic Pulmonary Hypertension - A Systematic Review and Meta-Analysis. <i>Circulation Journal</i> , 2019 , 83, 1660-1667	2.9	20
335	EULAR recommendations for the management of antiphospholipid syndrome in adults. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1296-1304	2.4	312
334	Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 1064-1072	15.4	43
333	Real-world persistence with direct oral anticoagulants (DOACs) in naïve patients with non-valvular atrial fibrillation. <i>International Journal of Cardiology</i> , 2019 , 288, 72-75	3.2	8
332	The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 49, 464-468	5.3	38
331	The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases. <i>Autoimmunity Reviews</i> , 2019 , 18, 406-414	13.6	39
330	Gender-Related Differences in Antiplatelet Therapy and Impact on 1-Year Clinical Outcome in Patients Presenting With ACS: The START ANTIPLATELET Registry. <i>Angiology</i> , 2019 , 70, 257-263	2.1	10
329	Triple Antiphospholipid (aPL) Antibodies Positivity Is Associated With Pregnancy Complications in aPL Carriers: A Multicenter Study on 62 Pregnancies. <i>Frontiers in Immunology</i> , 2019 , 10, 1948	8.4	17
328	Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 2069-2080	15.4	4
327	Antiplatelet treatment in acute coronary syndrome patients: Real-world data from the START-Antiplatelet Italian Registry. <i>PLoS ONE</i> , 2019 , 14, e0219676	3.7	7
326	Antiphospholipid Syndrome in Chronic Thromboembolic Pulmonary Hypertension: A Well-Defined Subgroup of Patients. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 1403-1408	7	14

325	Can we use NOACS in APS?. <i>Autoimmunity Reviews</i> , 2019 , 18, 102408	13.6	3
324	An in Vitro model to mimic the thrombotic occlusion of small vessels in catastrophic antiphospholipid syndrome (CAPS). <i>Lupus</i> , 2019 , 28, 1663-1668	2.6	2
323	Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry. <i>Journal of the American Heart Association</i> , 2019 , 8, e012596	6	13
322	X-Ray Crystallographic and Single-Molecule Fluorescence Studies of Beta-2 Glycoprotein I Reveal an Alternative Mechanism of Autoantibody Recognition. <i>Blood</i> , 2019 , 134, 91-91	2.2	
321	Discovery and characterization of 2 novel subpopulations of aPS/PT antibodies in patients at high risk of thrombosis. <i>Blood Advances</i> , 2019 , 3, 1738-1749	7.8	12
320	Prevalence of antiphospholipid (aPL) antibodies among patients with chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis. <i>Internal and Emergency Medicine</i> , 2019 , 14, 521-527	3.7	16
319	The benefit of betrixaban for the extended thromboprophylaxis in acutely ill medical patients. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 261-268	4	
318	Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 105, 1477-1491	6.1	12
317	Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. <i>Nature Reviews Cardiology</i> , 2019 , 16, 113-130	14.8	37
316	The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiONal Clinical Database and Repository. <i>Arthritis Care and Research</i> , 2019 , 71, 134-141	4.7	23
315	Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2019 , 126, 656-661	3.7	16
314	Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 639-646	7.6	48
313	Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants. <i>Journal of Thrombosis and Haemostasis</i> , 2018 , 16, 842-848	15.4	74
312	Pharmacokinetic and pharmacodynamic re-evaluation of a genetic-guided warfarin trial. <i>European Journal of Clinical Pharmacology</i> , 2018 , 74, 571-582	2.8	2
311	Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2018 , 16, 809-813	15.4	114
310	Point of Care Testing (POCT) to assess drug concentration in patients treated with non-vitamin K antagonist oral anticoagulants (NOACs). <i>Thrombosis Research</i> , 2018 , 163, 100-104	8.2	7
309	Thrombocytopenia in high-risk patients with antiphospholipid syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2018 , 16, 529-532	15.4	23
308	Commentary. <i>Clinical Chemistry</i> , 2018 , 64, 781	5.5	

307	Different safety profiles of oral anticoagulants in very elderly non-valvular atrial fibrillation patients. A retrospective propensity score matched cohort study. <i>International Journal of Cardiology</i> , 2018 , 265, 103-107	3.2	14
306	The vexed question of whether or not to measure levels of direct oral anticoagulants before surgery or invasive procedures. <i>Internal and Emergency Medicine</i> , 2018 , 13, 1029-1036	3.7	17
305	Epidemiology and Management of Patients With Acute Coronary Syndromes in Contemporary Real-World Practice: Evolving Trends From the EYESHOT Study to the START-ANTIPLATELET Registry. <i>Angiology</i> , 2018 , 69, 795-802	2.1	25
304	Laboratory Diagnostics of Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2018 , 44, 439-444	5.3	16
303	International collaborative study for the calibration of proposed International Standards for thromboplastin, rabbit, plain, and for thromboplastin, recombinant, human, plain. <i>Journal of Thrombosis and Haemostasis</i> , 2018 , 16, 142-149	15.4	12
302	Warfarin prescription in patients with nonvalvular atrial fibrillation and one non-gender-related risk factor (CHA DS VASc 1 or 2): A treatment dilemma. <i>Cardiovascular Therapeutics</i> , 2018 , 36, e12310	3.3	1
301	Mechanical prosthetic heart valves: Quality of anticoagulation and thromboembolic risk. The observational multicenter PLECTRUM study. <i>International Journal of Cardiology</i> , 2018 , 267, 68-73	3.2	18
300	The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2018 , 16, 1994-2002	15.4	19
299	Risk factors for intracranial hemorrhage during vitamin K antagonist therapy in patients with nonvalvular atrial fibrillation: A case-control study. <i>Cardiovascular Therapeutics</i> , 2018 , 36, e12458	3.3	1
298	Laboratory criteria for antiphospholipid syndrome: reply. <i>Journal of Thrombosis and Haemostasis</i> , 2018 , 16, 2117-2119	15.4	8
297	Diagnostics and treatment of thrombotic antiphospholipid syndrome (APS): A personal perspective. <i>Thrombosis Research</i> , 2018 , 169, 35-40	8.2	22
296	Catastrophic antiphospholipid syndrome: Lessons from 14 cases successfully treated in a single center. A narrative report. <i>Journal of Autoimmunity</i> , 2018 , 93, 124-130	15.5	17
295	Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. <i>Blood</i> , 2018 , 132, 1365-1371	15.1	359
294	Optimizing quality care for the oral vitamin K antagonists (VKAs). <i>Hematology American Society of Hematology Education Program</i> , 2018 , 2018, 332-338	3.1	7
293	Lupus anticoagulant identifies two distinct groups of patients with different antibody patterns. <i>Thrombosis Research</i> , 2018 , 172, 172-178	8.2	32
292	Risk of reoperation in bioprosthetic valve patients with indication for long-term anticoagulation. Results from the observational retrospective multicentre PLECTRUM study. <i>Open Heart</i> , 2018 , 5, e000837	3.7	3
291	Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry. <i>Internal and Emergency Medicine</i> , 2018 , 13, 1051-1058	3.7	18
290	McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2018 , 16, 1656	15.4	53

289	Impact of Chronic Renal Failure on Ischemic and Bleeding Events at 1 Year in Patients With Acute Coronary Syndrome (from the Multicenter START ANTIPLATELET Registry). <i>American Journal of Cardiology</i> , 2018 , 122, 936-943	3	10
288	Clinical value of anti-domain I- α -Glycoprotein 1 antibodies in antiphospholipid antibody carriers. A single centre, prospective observational follow-up study. <i>Clinica Chimica Acta</i> , 2018 , 485, 74-78	6.2	9
287	Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2017 , 53, 28-39	12.3	14
286	Comparison of HAS-BLED and HAS-BED Versus CHADS and CHADSVASC Stroke and Bleeding Scores in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2017 , 119, 1012-1016	3	16
285	The role of platelets in antiphospholipid syndrome. <i>Platelets</i> , 2017 , 28, 762-766	3.6	25
284	Reduction of annexin A5 anticoagulant ratio identifies antiphospholipid antibody-positive patients with adverse clinical outcomes. <i>Journal of Thrombosis and Haemostasis</i> , 2017 , 15, 1412-1421	15.4	9
283	Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago. <i>Internal and Emergency Medicine</i> , 2017 , 12, 1109-1119	3.7	25
282	Residual vein thrombosis and serial D-dimer for the long-term management of patients with deep venous thrombosis. <i>Thrombosis Research</i> , 2017 , 154, 35-41	8.2	15
281	Assessing the relative potency of (S)- and (R)-warfarin with a new PK-PD model, in relation to VKORC1 genotypes. <i>European Journal of Clinical Pharmacology</i> , 2017 , 73, 699-707	2.8	8
280	Detection of lupus anticoagulant in the era of direct oral anticoagulants. <i>Autoimmunity Reviews</i> , 2017 , 16, 173-178	13.6	51
279	Correlations between the enantio- and regio-selective metabolisms of warfarin. <i>Pharmacogenomics</i> , 2017 , 18, 133-142	2.6	
278	Clinical conundrums in antithrombotic therapy management: A Delphi Consensus panel. <i>International Journal of Cardiology</i> , 2017 , 249, 249-256	3.2	9
277	Data from a multidisciplinary poll of 178 expert physicians on the usage of non-vitamin K Oral Anticoagulants in patients with atrial fibrillation and venous thromboembolism. <i>Data in Brief</i> , 2017 , 15, 532-539	1.2	0
276	Consequences of warfarin suspension after major bleeding in very elderly patients with non valvular atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 1828-1830	7	7
275	Primary thromboprophylaxis with low-dose aspirin and antiphospholipid antibodies: Pro's and Con's. <i>Autoimmunity Reviews</i> , 2017 , 16, 1103-1108	13.6	11
274	Effectiveness and safety of oral anticoagulation with non-vitamin K antagonists compared to well-managed vitamin K antagonists in naïve patients with non-valvular atrial fibrillation: Propensity score matched cohort study. <i>International Journal of Cardiology</i> , 2017 , 249, 198-203	3.2	20
273	Lupus Anticoagulant Testing: Diluted Russell Viper Venom Time (dRVVT). <i>Methods in Molecular Biology</i> , 2017 , 1646, 169-176	1.4	7
272	Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant. <i>BMC Medicine</i> , 2017 , 15, 54	11.4	18

271	Antiphosphatidylserine/prothrombin antibodies as biomarkers to identify severe primary antiphospholipid syndrome. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017 , 55, 890-898	5.9	31
270	Population differences in S-warfarin pharmacokinetics among African Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms. <i>Pharmacogenomics Journal</i> , 2017 , 17, 494-500	3.5	14
269	Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. <i>Immunologic Research</i> , 2017 , 65, 17-24	4.3	58
268	Prevalence and predictors of dual antiplatelet therapy prolongation beyond one year in patients with acute coronary syndrome. <i>PLoS ONE</i> , 2017 , 12, e0186961	3.7	15
267	15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Treatment Trends Report 2017 , 317-338		16
266	The left atrial appendage: from embryology to prevention of thromboembolism. <i>European Heart Journal</i> , 2017 , 38, 877-887	9.5	41
265	Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial. <i>Lupus</i> , 2016 , 25, 301-6	2.6	60
264	Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study. <i>Journal of Thrombosis and Haemostasis</i> , 2016 , 14, 2194-2201	15.4	51
263	Pathogenesis of the antiphospholipid syndrome revisited: time to challenge the dogma: comment. <i>Journal of Thrombosis and Haemostasis</i> , 2016 , 14, 2561-2562	15.4	1
262	Mortality associated to atrial fibrillation still on the rise: United States, 1999 to 2014. <i>International Journal of Cardiology</i> , 2016 , 222, 788-789	3.2	4
261	Dyspnoea in a young woman: the opposite of every truth is just as true. <i>Internal and Emergency Medicine</i> , 2016 , 11, 95-9	3.7	
260	The challenges of lupus anticoagulants. <i>Expert Review of Hematology</i> , 2016 , 9, 389-400	2.8	24
259	Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics. <i>Thrombosis Research</i> , 2016 , 137, 178-183	8.2	105
258	Duration of anticoagulation after isolated pulmonary embolism. <i>European Respiratory Journal</i> , 2016 , 47, 1429-35	13.6	9
257	A pharmacokinetic-pharmacodynamic model for individualisation of an oral anticoagulation therapy. <i>Computer Aided Chemical Engineering</i> , 2016 , 2313-2318	0.6	
256	The SAME-TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE. A real-life inception cohort study. <i>Thrombosis and Haemostasis</i> , 2016 , 115, 1101-8	7	19
255	Molecular mapping of Thrombin (II)/II-glycoprotein I (IIgpl) interaction reveals how IIgpl affects II functions. <i>Biochemical Journal</i> , 2016 , 473, 4629-4650	3.8	11
254	A Bridging Protocol in High-Thrombotic Risk Mechanical Valve Bearers Undergoing Surgery or Invasive Procedures. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 2714-2715	15.1	2

253	Contemporary Burden of Atrial Fibrillation and Associated Mortality in Northeastern Italy. <i>American Journal of Cardiology</i> , 2016 , 118, 720-4	3	6
252	APS - Diagnostics and challenges for the future. <i>Autoimmunity Reviews</i> , 2016 , 15, 1031-1033	13.6	24
251	Reasons for and consequences of vitamin K antagonist discontinuation in very elderly patients with non-valvular atrial fibrillation. <i>Journal of Thrombosis and Haemostasis</i> , 2016 , 14, 2124-2131	15.4	20
250	Laboratory testing for antiphospholipid syndrome. <i>International Journal of Laboratory Hematology</i> , 2016 , 38 Suppl 1, 27-31	2.5	21
249	The Three Players of Mechanical Valve Thrombosis: Cancer, Anticancer Therapy, and Thromboprophylaxis. <i>Journal of Heart Valve Disease</i> , 2016 , 25, 522-524		
248	Relationship between antiphosphatidylserine/prothrombin and conventional antiphospholipid antibodies in primary antiphospholipid syndrome. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015 , 53, 1265-70	5.9	22
247	Antibodies to Domain 4/5 (Dm4/5) of β -Glycoprotein 1 (β GP1) in different antiphospholipid (aPL) antibody profiles. <i>Thrombosis Research</i> , 2015 , 136, 161-3	8.2	34
246	Cancer as a risk factor for stroke in atrial fibrillation patients receiving long-term oral anticoagulant therapy. <i>Thrombosis Research</i> , 2015 , 136, 488	8.2	4
245	Minimizing the risk of hemorrhagic stroke during anticoagulant therapy for atrial fibrillation. <i>Expert Opinion on Drug Safety</i> , 2015 , 14, 683-95	4.1	9
244	Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. <i>Autoimmunity Reviews</i> , 2015 , 14, 192-200	13.6	86
243	Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant. <i>Thrombosis Research</i> , 2015 , 135, 46-9	8.2	55
242	Antiphospholipid syndrome and the heart: a case series and literature review. <i>Autoimmunity Reviews</i> , 2015 , 14, 214-22	13.6	58
241	The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation. <i>PLoS ONE</i> , 2015 , 10, e0124719	3.7	38
240	To treat or not to treat very elderly naïve patients with atrial fibrillation with vitamin K antagonists (VKA): results from the VENPAF cohort. <i>Internal and Emergency Medicine</i> , 2015 , 10, 795-804	3.7	17
239	The Paradox of Lupus Anticoagulant. <i>Rare Diseases of the Immune System</i> , 2015 , 13-23	0.2	
238	Managing dentoalveolar surgical procedures in patients taking new oral anticoagulants. <i>Odontology / the Society of the Nippon Dental University</i> , 2015 , 103, 258-63	3.6	14
237	Antiphospholipid syndrome: antibodies to Domain 1 of β -glycoprotein 1 correctly classify patients at risk. <i>Journal of Thrombosis and Haemostasis</i> , 2015 , 13, 782-7	15.4	89
236	A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naïve Patients with Non-Valvular Atrial Fibrillation. <i>PLoS ONE</i> , 2015 , 10, e0145318	3.7	23

235	Diagnosis and therapy of antiphospholipid syndrome. <i>Polish Archives of Internal Medicine</i> , 2015 , 125, 672-7	1.9	11
234	Heart and APS. <i>Rare Diseases of the Immune System</i> , 2015 , 127-150	0.2	
233	Lupus Anticoagulant Testing 2014 , 731-734		
232	Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. <i>Autoimmunity Reviews</i> , 2014 , 13, 281-91	13.6	112
231	Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A 'state-of-the-art' paper. <i>European Heart Journal</i> , 2014 , 35, 2213-23b	9.5	55
230	Clinical relevance of Eglycoprotein-I plasma levels in antiphospholipid syndrome (APS). <i>Current Rheumatology Reports</i> , 2014 , 16, 424	4.9	8
229	D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. <i>Blood</i> , 2014 , 124, 196-203	2.2	127
228	An approach to differential diagnosis of antiphospholipid antibody syndrome and related conditions. <i>Scientific World Journal, The</i> , 2014 , 2014, 341342	2.2	13
227	The paradox of the lupus anticoagulant: history and perspectives. <i>Seminars in Thrombosis and Hemostasis</i> , 2014 , 40, 860-5	5.3	8
226	Laboratory tests during direct oral anticoagulant treatment? Yes. <i>Internal and Emergency Medicine</i> , 2013 , 8, 371-2	3.7	11
225	Investigational anticoagulants for hematological conditions: a new generation of therapies. <i>Expert Opinion on Investigational Drugs</i> , 2013 , 22, 1281-94	5.9	6
224	Ferritin in the antiphospholipid syndrome and its catastrophic variant (cAPS). <i>Lupus</i> , 2013 , 22, 1327-35	2.6	40
223	Chronic thromboembolic pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 2013 , 62, D92-9	15.1	404
222	The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study. <i>Journal of Thrombosis and Haemostasis</i> , 2013 , 11, 1053-8	15.4	32
221	Major bleeding in patients undergoing PCI and triple or dual antithrombotic therapy: a parallel-cohort study. <i>Journal of Thrombosis and Thrombolysis</i> , 2013 , 35, 178-84	5.1	14
220	Hospitalized patients with atrial fibrillation compared to those included in recent trials on novel oral anticoagulants: a population-based study. <i>European Journal of Internal Medicine</i> , 2013 , 24, 318-23	3.9	20
219	A combination therapy protocol of plasmapheresis, intravenous immunoglobulins and betamethasone to treat anti-Ro/La-related congenital atrioventricular block. A case series and review of the literature. <i>Autoimmunity Reviews</i> , 2013 , 12, 768-73	13.6	36
218	Clinical management of rivaroxaban-treated patients. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 655-67	4.7	13

217	Correct laboratory approach to APS diagnosis and monitoring. <i>Autoimmunity Reviews</i> , 2013 , 12, 832-4	13.6	45
216	Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile. <i>Journal of Thrombosis and Haemostasis</i> , 2013 , 11, 1527-31	15.4	60
215	Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results: a reply to a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2013 , 11, 1205-6	15.4	1
214	β ₂ -Glycoprotein I binds to thrombin and selectively inhibits the enzyme procoagulant functions. <i>Journal of Thrombosis and Haemostasis</i> , 2013 , 11, 1093-102	15.4	21
213	The influence of factor V Leiden and G20210A prothrombin mutation on the presence of residual vein obstruction after idiopathic deep-vein thrombosis of the lower limbs. <i>Thrombosis and Haemostasis</i> , 2013 , 109, 510-6	7	6
212	Variability in exposure of epitope G40-R43 of domain I in commercial anti-beta2-glycoprotein I IgG ELISAs. <i>PLoS ONE</i> , 2013 , 8, e71402	3.7	30
211	Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome. <i>Thrombosis and Haemostasis</i> , 2013 , 109, 901-8	7	26
210	Ultrasound phonocardiography for detecting thrombotic formations on bileaflet mechanical heart valves. <i>Journal of Heart Valve Disease</i> , 2013 , 22, 828-36		4
209	High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: 'PROS' and 'CONS'. <i>Autoimmunity Reviews</i> , 2012 , 11, 577-80	13.6	25
208	Aspirin and recurrent venous thromboembolism in patients with symptomatic atherosclerosis: retrospective cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2012 , 10, 2205-6	15.4	7
207	Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. <i>Journal of Thrombosis and Haemostasis</i> , 2012 , 10, 1979-87	15.4	24
206	Current anticoagulant safety. <i>Expert Opinion on Drug Safety</i> , 2012 , 11, 401-13	4.1	4
205	Risk-based secondary prevention of obstetric antiphospholipid syndrome. <i>Lupus</i> , 2012 , 21, 741-3	2.6	7
204	Higher levels of plasma matrix metalloproteinase-2 are associated with a significantly increased risk of arterial thrombosis in patients with the antiphospholipid syndrome. <i>International Journal of Cardiology</i> , 2012 , 160, 149-51	3.2	3
203	ISTH guidelines on lupus anticoagulant testing. <i>Thrombosis Research</i> , 2012 , 130 Suppl 1, S76-7	8.2	29
202	Biological variation of INR in stable patients on long-term anticoagulation with warfarin. <i>Thrombosis Research</i> , 2012 , 130, 535-7	8.2	9
201	Management of special conditions in patients on vitamin K antagonists. <i>Internal and Emergency Medicine</i> , 2012 , 7, 407-13	3.7	1
200	Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2012 , 92, 746-56	6.1	51

199	Development of artificial neural network-based algorithms for the classification of bileaflet mechanical heart valve sounds. <i>International Journal of Artificial Organs</i> , 2012 , 35, 279-87	1.9	1
198	Family history of venous thrombosis or sudden death as a risk factor for venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2012 , 107, 1191-2	7	8
197	The negative predictive value of D-dimer on the risk of recurrent venous thromboembolism in patients with multiple previous events: a prospective cohort study (the PROLONG PLUS study). <i>American Journal of Hematology</i> , 2012 , 87, 713-5	7.1	7
196	An unusual acute coronary syndrome: undisclosed disease hidden under a confounding clinical presentation. <i>Internal and Emergency Medicine</i> , 2012 , 7 Suppl 1, S29-31	3.7	
195	Antiphosphatidylserine/prothrombin antibodies in primary antiphospholipid syndrome. <i>Lupus</i> , 2012 , 21, 787-9	2.6	26
194	Interpretation of laboratory data and need for reference laboratories. <i>Lupus</i> , 2012 , 21, 732-3	2.6	6
193	What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts?. <i>Seminars in Thrombosis and Hemostasis</i> , 2012 , 38, 322-7	5.3	51
192	A combination therapy to treat second-degree anti-Ro/La-related congenital heart block: a strategy to avoid stable third-degree heart block?. <i>Lupus</i> , 2012 , 21, 666-71	2.6	30
191	Standardization of lupus anticoagulant. The Lupus Anticoagulant Sensitivity Index (LASI). <i>Lupus</i> , 2012 , 21, 715-7	2.6	1
190	Circulating β glycoprotein I-IgG anti- β glycoprotein I immunocomplexes in patients with definite antiphospholipid syndrome. <i>Lupus</i> , 2012 , 21, 784-6	2.6	15
189	Secondary prevention in thrombotic antiphospholipid syndrome. <i>Lupus</i> , 2012 , 21, 734-5	2.6	10
188	Task Force Report on the Management of Thrombosis in Antiphospholipid Syndrome 2012 , 167-179		
187	Variability in Exposure of Epitope G40-R43 of Domain I in Commercial Anti- β -Glycoprotein I IgG Elisas Influences the Diagnosis of the Antiphospholipid Syndrome. <i>Blood</i> , 2012 , 120, 632-632	2.2	
186	Emerging anticoagulants. <i>Expert Opinion on Emerging Drugs</i> , 2011 , 16, 31-44	3.7	7
185	'Criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010. <i>Lupus</i> , 2011 , 20, 182-90	2.6	61
184	Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. <i>Lupus</i> , 2011 , 20, 206-18	2.6	351
183	Standardization of lupus anticoagulant. Feasibility study of a calibration model to minimize between-method variability. <i>Thrombosis Research</i> , 2011 , 127, 589-94	8.2	8
182	Antibodies to Domain I of (β)Glycoprotein I are in close relation to patients risk categories in Antiphospholipid Syndrome (APS). <i>Thrombosis Research</i> , 2011 , 128, 583-6	8.2	60

181	APS--controversies in diagnosis and management, critical overview of current guidelines. <i>Thrombosis Research</i> , 2011 , 127 Suppl 3, S51-2	8.2	21
180	Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). <i>Thrombosis and Haemostasis</i> , 2011 , 106, 868-76	7	135
179	Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. <i>Blood</i> , 2011 , 118, 4714-8	2.2	302
178	Long-term use of vitamin K antagonists and incidence of cancer: a population-based study. <i>Blood</i> , 2011 , 117, 1707-9	2.2	39
177	Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment. <i>Journal of Internal Medicine</i> , 2011 , 270, 110-22	10.8	76
176	Antiphospholipid syndrome: interpretation of laboratory data. <i>Journal of Thrombosis and Haemostasis</i> , 2011 , 9, 402-3	15.4	12
175	False-negative or false-positive: laboratory diagnosis of lupus anticoagulant at the time of commencement of anticoagulant: a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2011 , 9, 1435-6; author reply 1436-7	15.4	7
174	More on: laboratory investigation of lupus anticoagulants: mixing studies are sometimes required. <i>Journal of Thrombosis and Haemostasis</i> , 2011 , 9, 2126-7	15.4	19
173	Prescription of vitamin K inhibitors in low-risk patients with atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2011 , 31, 501-2	5.1	0
172	A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty. <i>Journal of Thrombosis and Thrombolysis</i> , 2011 , 31, 233-4	5.1	7
171	Comparative classification of thrombotic formations on bileaflet mechanical heart valves by phonographic analysis. <i>Journal of Artificial Organs</i> , 2011 , 14, 100-11	1.8	5
170	Low molecular weight heparin (parnaparin) for cardioembolic events prevention in patients with atrial fibrillation undergoing elective electrical cardioversion: a prospective cohort study. <i>Internal and Emergency Medicine</i> , 2011 , 6, 117-23	3.7	3
169	Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. <i>Rheumatology</i> , 2011 , 50, 1684-9	3.9	143
168	VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. <i>Pharmacogenomics</i> , 2011 , 12, 15-25	2.6	52
167	Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1083-6	2.4	122
166	Comorbidities, alone and in combination with D-dimer, as risk factors for recurrence after a first episode of unprovoked venous thromboembolism in the extended follow-up of the PROLONG study. <i>Thrombosis and Haemostasis</i> , 2010 , 103, 1152-60	7	13
165	Argatroban in the management of heparin-induced thrombocytopenia. <i>Vascular Health and Risk Management</i> , 2010 , 6, 813-9	4.4	10
164	The redox enzyme p66Shc contributes to diabetes and ischemia-induced delay in cutaneous wound healing. <i>Diabetes</i> , 2010 , 59, 2306-14	0.9	66

163	Antiphospholipid syndrome: critical analysis of the diagnostic path. <i>Lupus</i> , 2010 , 19, 428-31	2.6	28
162	Dosing of clopidogrel and aspirin in acute coronary syndromes. <i>New England Journal of Medicine</i> , 2010 , 363, 2466-7; author reply 2467-8	59.2	
161	Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. <i>Archives of Internal Medicine</i> , 2010 , 170, 1710-6		228
160	Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA). <i>Thrombosis Research</i> , 2010 , 126, 150-3	8.2	28
159	Cancer prevention and vitamin K antagonists: an overview. <i>Thrombosis Research</i> , 2010 , 125 Suppl 2, S1035-5		9
158	Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study. <i>Blood</i> , 2010 , 115, 481-8	2.2	120
157	Lower versus standard intensity oral anticoagulant therapy (OAT) in elderly warfarin-experienced patients with non-valvular atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2010 , 103, 442-9	7	37
156	Deep venous thrombosis after surgery for inflammatory bowel disease: is standard dose low molecular weight heparin prophylaxis enough?. <i>World Journal of Surgery</i> , 2010 , 34, 1629-36	3.3	28
155	Right ventricular dysfunction in patients diagnosed with pulmonary embolism. <i>Internal and Emergency Medicine</i> , 2010 , 5, 451-2	3.7	2
154	Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep vein thrombosis in the prolong study. <i>European Journal of Vascular and Endovascular Surgery</i> , 2010 , 39, 356-65	2.3	45
153	Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. <i>Arthritis Care and Research</i> , 2010 , 62, 302-7	4.7	81
152	Chemical synthesis and characterization of wild-type and biotinylated N-terminal domain 1-64 of beta2-glycoprotein I. <i>Protein Science</i> , 2010 , 19, 1065-78	6.3	17
151	Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 237-42	15.4	392
150	The risk of cancer in patients with venous thromboembolism does not exceed that expected in the general population after the first 6 months. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 1126-7	15.4	15
149	Sex, age and normal post-anticoagulation D-dimer as risk factors for recurrence after idiopathic venous thromboembolism in the Prolong study extension. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 1933-42	15.4	26
148	Application of wavelet analysis to the phonocardiographic signal of mechanical heart valve closing sounds. <i>International Journal of Artificial Organs</i> , 2009 , 32, 166-72	1.9	5
147	Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study. <i>Circulation</i> , 2009 , 119, 2920-7	16.7	115
146	Recovery from catastrophic antiphospholipid syndrome by a plasma exchange procedure: report of four cases and review of the literature. <i>Autoimmunity Reviews</i> , 2009 , 8, 297-301	13.6	26

145	Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention. <i>American Journal of Hematology</i> , 2009 , 84, 579-83	7.1	12
144	Bileaflet mechanical heart valve closing sounds: in vitro classification by phonocardiographic analysis. <i>Journal of Artificial Organs</i> , 2009 , 12, 172-81	1.8	8
143	Effectiveness and safety of a management protocol to correct over-anticoagulation with oral vitamin K: a retrospective study of 1,043 cases. <i>Journal of Thrombosis and Thrombolysis</i> , 2009 , 27, 340-7	5.1	26
142	Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study. <i>Journal of Thrombosis and Thrombolysis</i> , 2009 , 28, 381-8	5.1	25
141	Mild inflammation may switch on again atrial fibrillation after successful electrical cardioversion. <i>Internal and Emergency Medicine</i> , 2009 , 4, 277-8	3.7	2
140	The long-term risk of cancer in patients with a first episode of venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2009 , 7, 546-51	15.4	29
139	Antiphospholipid syndrome classification criteria: comments to the Letter of Jakub Swadzba and Jacek Musial. <i>Journal of Thrombosis and Haemostasis</i> , 2009 , 7, 503	15.4	4
138	Risk stratification and outcomes in hemodynamically stable patients with acute pulmonary embolism: a prospective, multicentre, cohort study with three months of follow-up. <i>Journal of Thrombosis and Haemostasis</i> , 2009 , 7, 938-44	15.4	67
137	Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2009 , 7, 1737-40	15.4	834
136	The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. <i>Journal of Thrombosis and Haemostasis</i> , 2009 , 7, 1767-73	15.4	210
135	Prevalence of heart diseases in patients with pulmonary embolism with and without peripheral venous thrombosis: findings from a cross-sectional survey. <i>European Journal of Internal Medicine</i> , 2009 , 20, 470-3	3.9	29
134	Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy. <i>Thrombosis Research</i> , 2009 , 123, 482-7	8.2	88
133	Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function. <i>Thrombosis Research</i> , 2009 , 123, 444-51	8.2	39
132	Is the analysis over the time domain or over the frequency domain significant for the detection of bileaflet mechanical heart valve dysfunction?. <i>Annals of Thoracic Surgery</i> , 2009 , 87, 986-7; author reply 987-8	2.7	3
131	Prasugrel for the treatment of patients with acute coronary syndrome. <i>Vascular Health and Risk Management</i> , 2009 , 5, 321-4	4.4	1
130	Anti- β -glycoprotein I ELISA assay: The influence of different antigen preparations. <i>Thrombosis and Haemostasis</i> , 2009 , 101, 789-791	7	11
129	An oral vitamin K protocol to reverse over-anticoagulation in patients presenting with an International Normalised Ratio above 10.0. <i>Thrombosis and Haemostasis</i> , 2009 , 101, 410-411	7	5
128	An oral vitamin K protocol to reverse over-anticoagulation in patients presenting with an International Normalised Ratio above 10.0. <i>Thrombosis and Haemostasis</i> , 2009 , 101, 410-1	7	2

127	Anti-beta(2)-glycoprotein I ELISA assay: the influence of different antigen preparations. <i>Thrombosis and Haemostasis</i> , 2009 , 101, 789-91	7	3
126	A contribution to the debate on the laboratory criteria that define the antiphospholipid syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2008 , 6, 1048-9	15.4	25
125	Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification. <i>Journal of Thrombosis and Haemostasis</i> , 2008 , 6, 1693-6	15.4	104
124	Plasma exchange for the management of the catastrophic antiphospholipid syndrome: importance of the type of fluid replacement. <i>Journal of Internal Medicine</i> , 2008 , 264, 201-3	10.8	35
123	Antibodies to oxidized LDL/beta2-glycoprotein I in antiphospholipid syndrome patients with venous and arterial thromboembolism. <i>Thrombosis Research</i> , 2008 , 122, 556-6	8.2	19
122	Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. <i>Lancet, The</i> , 2008 , 371, 315-21	40	217
121	2008 ,		4
120	D-dimer testing and recurrent venous thromboembolism after unprovoked pulmonary embolism: A post-hoc analysis of the prolong extension study. <i>Thrombosis and Haemostasis</i> , 2008 , 100, 718-721	7	5
119	D-dimer testing and recurrent venous thromboembolism after unprovoked pulmonary embolism: A post-hoc analysis of the prolong extension study. <i>Thrombosis and Haemostasis</i> , 2008 , 100, 718-21	7	2
118	Low-intensity oral anticoagulant plus low-dose aspirin during the first six months versus standard-intensity oral anticoagulant therapy after mechanical heart valve replacement: a pilot study of low-intensity warfarin and aspirin in cardiac prostheses (LIWACAP). <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2007 , 13, 241-8	3.3	25
117	Thrombophilia in young patients with cryptogenic stroke and patent foramen ovale (PFO). <i>Thrombosis and Haemostasis</i> , 2007 , 98, 906-907	7	14
116	Knowledges about herbal products among subjects on warfarin therapy and patient-physician relationship: a pilot study. <i>Pharmacoepidemiology and Drug Safety</i> , 2007 , 16, 1014-7	2.6	10
115	A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2007 , 81, 529-38	6.1	115
114	Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. <i>Journal of Thrombosis and Haemostasis</i> , 2007 , 5, 925-30	15.4	84
113	Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature. <i>Autoimmunity Reviews</i> , 2007 , 6, 196-202	13.6	58
112	Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). <i>Journal of Thrombosis and Thrombolysis</i> , 2007 , 23, 83-91	5.1	108
111	Management of patients on long-term oral anticoagulant therapy undergoing elective surgery: survey of the clinical practice in the Italian anticoagulation clinics. <i>Internal and Emergency Medicine</i> , 2007 , 2, 280-4	3.7	7
110	A comparison of lupus anticoagulant-positive patients with clinical picture of antiphospholipid syndrome and those without. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007 , 27, e309-10	9.4	33

109	The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. <i>Haematologica</i> , 2007 , 92, 199-205	6.6	573
108	LUPUS ANTICOAGULANT TESTING 2007 , 733-739		
107	The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. <i>Annals of Internal Medicine</i> , 2007 , 147, 766-74	8	151
106	Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-beta2-Glycoprotein I activity. <i>Thrombosis Research</i> , 2007 , 120, 127-33	8.2	67
105	Thrombophilia in young patients with cryptogenic stroke and patent foramen ovale (PFO). <i>Thrombosis and Haemostasis</i> , 2007 , 98, 906-7	7	3
104	Monitoring oral anticoagulants: new strategies for an emerging problem. <i>Internal and Emergency Medicine</i> , 2006 , 1, 3-4	3.7	5
103	Positive stress test in a patient with patent coronary artery grafts. <i>Internal and Emergency Medicine</i> , 2006 , 1, 296-9	3.7	1
102	Use of a new silica clotting time for diagnosing lupus anticoagulant in patients who meet the clinical criteria for antiphospholipid syndrome. <i>Journal of Clinical Laboratory Analysis</i> , 2006 , 20, 15-8	3	8
101	Should patients with mitral stenosis and atrial fibrillation receive combined antithrombotic therapy?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006 , 3, 412-3		
100	The diagnosis of the antiphospholipid syndrome. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2006 , 35, 175-80		8
99	Management of oral anticoagulant treatment in patients with venous thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2006 , 32, 781-6	5.3	8
98	Sex and anticoagulation in patients with idiopathic venous thromboembolism. <i>Lancet, The</i> , 2006 , 368, 342-3	40	6
97	D-dimer testing to determine the duration of anticoagulation therapy. <i>New England Journal of Medicine</i> , 2006 , 355, 1780-9	59.2	493
96	Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. <i>Thrombosis and Haemostasis</i> , 2006 , 96, 337-41	7	135
95	Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. <i>Pharmacogenetics and Genomics</i> , 2006 , 16, 101-10	1.9	285
94	Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. <i>Journal of Thrombosis and Haemostasis</i> , 2006 , 4, 1891-6	15.4	128
93	Worldwide management of oral anticoagulant therapy: the ISAM study. <i>Journal of Thrombosis and Thrombolysis</i> , 2006 , 21, 73-7	5.1	96
92	Efficacy and safety of nadroparin in the treatment of pregnant women with antiphospholipid syndrome: a prospective cohort study. <i>Lupus</i> , 2005 , 14, 120-8	2.6	9

91	Antibody profiles for the diagnosis of antiphospholipid syndrome. <i>Thrombosis and Haemostasis</i> , 2005 , 93, 1147-52	7	212
90	Antithrombotic strategies for atrial fibrillation: on the threshold of changes? No. <i>Journal of Thrombosis and Haemostasis</i> , 2005 , 3, 433-5	15.4	
89	Anti-beta2-glycoprotein I antibody testing in the laboratory diagnosis of antiphospholipid syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2005 , 3, 1158-9	15.4	3
88	Risks factors for highly unstable response to oral anticoagulation: a case-control study. <i>British Journal of Haematology</i> , 2005 , 129, 72-8	4.5	72
87	Apolipoprotein E (APOE) and warfarin dosing in an Italian population. <i>European Journal of Clinical Pharmacology</i> , 2005 , 61, 781-3	2.8	27
86	New trends in anticoagulant treatments. <i>Lupus</i> , 2005 , 14, 789-93	2.6	2
85	From acute pulmonary embolism to chronic thromboembolic pulmonary hypertension. <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , 2005 , 6, 830-3		2
84	Chronic thromboembolic pulmonary hypertension. <i>New England Journal of Medicine</i> , 2004 , 351, 1693; author reply 1693	59.2	0
83	Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. <i>New England Journal of Medicine</i> , 2004 , 350, 2257-64	59.2	1327
82	A two-step coagulation test to identify antibeta-glycoprotein I lupus anticoagulants. <i>Journal of Thrombosis and Haemostasis</i> , 2004 , 2, 702-7	15.4	71
81	Long-term warfarin use to prevent both stroke and dementia in subjects with atrial fibrillation?. <i>Journal of Thrombosis and Haemostasis</i> , 2004 , 2, 1871-2	15.4	2
80	Low Molecular Weight Heparin during Surgery in Parientns on Long Term Oral Anticoagulant Treatment (OAT): A Prospective Observational Study.. <i>Blood</i> , 2004 , 104, 4063-4063	2.2	1
79	Features associated with epilepsy in the antiphospholipid syndrome. <i>Journal of Rheumatology</i> , 2004 , 31, 1344-8	4.1	75
78	New trends in anticoagulant therapy. <i>Israel Medical Association Journal</i> , 2004 , 6, 479-81	0.9	5
77	Lupus anticoagulant (LA) testing: performance of clinical laboratories assessed by a national survey using lyophilized affinity-purified immunoglobulin with LA activity. <i>Clinical Chemistry</i> , 2003 , 49, 1608-14	5.5	61
76	Mechanical prosthetic heart valve thrombosis despite optimal anticoagulation in a patient with congenital thrombophilia (factor V Leiden). <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2003 , 9, 89-90	3.3	1
75	Oral anticoagulant therapy in patients with atrial fibrillation. <i>Seminars in Vascular Medicine</i> , 2003 , 3, 333-8		1
74	Prevention of thromboembolism in patients with mitral stenosis and associated atrial fibrillation: effectiveness of low intensity (INR target 2) oral anticoagulant treatment. <i>Thrombosis and Haemostasis</i> , 2003 , 89, 760-764	7	15

73	Prevalence and clinical correlations of antibodies against six beta2-glycoprotein-I-related peptides in the antiphospholipid syndrome. <i>Journal of Clinical Immunology</i> , 2003 , 23, 377-83	5.7	44
72	A Comparison Between Six- and Four-Week Intervals in Surveillance of Oral Anticoagulant Treatment. <i>American Journal of Clinical Pathology</i> , 2003 , 120, 944-947	1.9	19
71	A comparison between six- and four-week intervals in surveillance of oral anticoagulant treatment. <i>American Journal of Clinical Pathology</i> , 2003 , 120, 944-7	1.9	9
70	Prevention of thromboembolism in patients with mitral stenosis and associated atrial fibrillation: effectiveness of low intensity (INR target 2) oral anticoagulant treatment. <i>Thrombosis and Haemostasis</i> , 2003 , 89, 760-4	7	2
69	Association of the G20210A mutation in the factor II gene with systemic embolism in nonvalvular atrial fibrillation. <i>American Journal of Cardiology</i> , 2002 , 90, 545-7	3	17
68	Diabetic ketosis activates lymphomonocyte-inducible nitric oxide synthase. <i>Diabetic Medicine</i> , 2002 , 19, 777-83	3.5	12
67	Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. <i>Clinical Pharmacology and Therapeutics</i> , 2002 , 72, 702-10	6.1	272
66	Oral anticoagulant treatment in very elderly patients with atrial fibrillation. <i>Comprehensive Therapy</i> , 2001 , 27, 7-10		2
65	A simple scheme to initiate oral anticoagulant treatment in outpatients with nonrheumatic atrial fibrillation. <i>American Journal of Cardiology</i> , 2001 , 88, 1214-6	3	16
64	The Risk of Overdiagnosis of Antiphospholipid Antibody Syndrome. <i>Thrombosis and Haemostasis</i> , 2001 , 86, 933-933	7	6
63	Oral Anticoagulant Therapy in Patients with Nonrheumatic Atrial Fibrillation and Risk of Bleeding. <i>Thrombosis and Haemostasis</i> , 2001 , 85, 418-422	7	123
62	Some Patients with Antiphospholipid Syndrome Express hitherto Undescribed Antibodies to Cardiolipin-binding Proteins. <i>Thrombosis and Haemostasis</i> , 2001 , 85, 57-62	7	33
61	Some patients with antiphospholipid syndrome express hitherto undescribed antibodies to cardiolipin-binding proteins. <i>Thrombosis and Haemostasis</i> , 2001 , 85, 57-62	7	2
60	Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study. <i>Thrombosis and Haemostasis</i> , 2001 , 85, 418-22	7	22
59	Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PProgram for Oral Anticoagulant Treatment). <i>Haematologica</i> , 2001 , 86, 1060-70	6.6	71
58	The Management of Oral Anticoagulant Therapy: The Patient's Point of View. <i>Thrombosis and Haemostasis</i> , 2000 , 83, 49-53	7	45
57	A Comparison of the Safety and Efficacy of Oral Anticoagulation for the Treatment of Venous Thromboembolic Disease in Patients with or without Malignancy. <i>Thrombosis and Haemostasis</i> , 2000 , 84, 805-810	7	181
56	Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study. <i>Archives of Internal Medicine</i> , 2000 , 160, 470-8		101

55	Simple and safe method to prepare patients with prosthetic heart valves for surgical dental procedures. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2000 , 6, 90-3	3.3	27
54	Accuracy of a portable prothrombin time monitor (Coagucheck) in patients on chronic oral anticoagulant therapy: a prospective multicenter study. <i>Thrombosis Research</i> , 2000 , 100, 279-86	8.2	37
53	Comparison between routine laboratory prothrombin time measurements and fingerstick determinations using a near-patient testing device (Pro-Time). <i>Thrombosis Research</i> , 2000 , 97, 495-8	8.2	11
52	Effect of anti-beta2glycoprotein I Lupus Anticoagulants on fibrin polymerization and fibrinolysis. <i>Autoimmunity</i> , 2000 , 32, 39-44	3	3
51	The management of oral anticoagulant therapy: the patient's point of view. <i>Thrombosis and Haemostasis</i> , 2000 , 83, 49-53	7	17
50	Assessment of patient capability to self-adjust oral anticoagulant dose: a multicenter study on home use of portable prothrombin time monitor (COAGUCHECK). <i>Haematologica</i> , 2000 , 85, 826-31	6.6	16
49	A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. <i>Thrombosis and Haemostasis</i> , 2000 , 84, 805-10	7	54
48	dRVVT Is more Sensitive than KCT or TTI for Detecting Lupus Anticoagulant Activity of Anti- β -glycoprotein I Autoantibodies. <i>Thrombosis and Haemostasis</i> , 1999 , 81, 256-258	7	67
47	Procoagulant Effect of Anti β -Glycoprotein I Antibodies With Lupus Anticoagulant Activity. <i>Blood</i> , 1999 , 94, 3814-3819	2.2	21
46	[Anti-beta2 glycoprotein I-beta2 glycoprotein I] immune complexes in patients with antiphospholipid syndrome and other autoimmune diseases. <i>Lupus</i> , 1999 , 8, 121-6	2.6	18
45	Procoagulant Effect of Anti β -Glycoprotein I Antibodies With Lupus Anticoagulant Activity. <i>Blood</i> , 1999 , 94, 3814-3819	2.2	
44	dRVVT is more sensitive than KCT or TTI for detecting lupus anticoagulant activity of anti-beta2-glycoprotein I autoantibodies. <i>Thrombosis and Haemostasis</i> , 1999 , 81, 256-8	7	2
43	Procoagulant effect of anti-beta2-glycoprotein I antibodies with lupus anticoagulant activity. <i>Blood</i> , 1999 , 94, 3814-9	2.2	2
42	Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation. <i>American Journal of Cardiology</i> , 1998 , 82, 433-7	3	92
41	Initiation of Warfarin Treatment in Outpatients with Nonrheumatic Atrial Fibrillation: A Scheme for Early Indication of Maintenance Dose. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1998 , 4, 274-276	3.3	6
40	Utilization of Dilute Russell's Viper Venom Time to Detect Autoantibodies against β -Glycoprotein I which Express Anticoagulant Activity in the Presence but not in the Absence of Exogenous Phospholipids. <i>Thrombosis and Haemostasis</i> , 1997 , 77, 123-126	7	17
39	A Comparison of a Moderate with Moderate-high Intensity Oral Anticoagulant Treatment in Patients with Mechanical Heart Valve Prostheses. <i>Thrombosis and Haemostasis</i> , 1997 , 77, 0839-0844	7	34
38	Thrombotic Events during Oral Anticoagulant Treatment: Results of the Inception-cohort, Prospective, Collaborative ISCOAT Study. <i>Thrombosis and Haemostasis</i> , 1997 , 78, 1438-1443	7	72

37	Utilization of dilute Russell's viper venom time to detect autoantibodies against beta 2-glycoprotein I which express anticoagulant activity in the presence but not in the absence of exogenous phospholipids. <i>Thrombosis and Haemostasis</i> , 1997 , 77, 123-6	7	1
36	Thrombotic events during oral anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study: ISCOAT study group (Italian Study on Complications of Oral Anticoagulant Therapy). <i>Thrombosis and Haemostasis</i> , 1997 , 78, 1438-43	7	25
35	Low intensity warfarin therapy. <i>Haematologica</i> , 1997 , 82, 710-2	6.6	1
34	Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. <i>Lancet, The</i> , 1996 , 348, 423-8	40	1105
33	High blood ketone body concentration in type 2 non-insulin dependent diabetic patients. <i>Journal of Endocrinological Investigation</i> , 1996 , 19, 99-105	5.2	34
32	Immunosuppressive treatment in a heart transplantation candidate with antiphospholipid syndrome. <i>Clinical Rheumatology</i> , 1996 , 15, 504-7	3.9	10
31	Autoantibodies to Phospholipid-binding Plasma Proteins in Patients with Thrombosis and Phospholipid-reactive Antibodies. <i>Thrombosis and Haemostasis</i> , 1996 , 75, 721-724	7	108
30	Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. <i>Thrombosis and Haemostasis</i> , 1996 , 75, 721-4	7	17
29	Binding of autoimmune cardiolipin-reactive antibodies to heparin: a mechanism of thrombosis?. <i>Thrombosis Research</i> , 1995 , 78, 371-8	8.2	8
28	Anti beta 2-glycoprotein I antibodies in a patient with catastrophic antiphospholipid syndrome. <i>Clinical Rheumatology</i> , 1995 , 14, 646-9	3.9	5
27	Autoimmune antiphospholipid antibodies are directed against a cryptic epitope expressed when beta 2-glycoprotein I is bound to a suitable surface. <i>Thrombosis and Haemostasis</i> , 1995 , 73, 29-34	7	18
26	Autoimmune Antiphospholipid Antibodies Are Directed against a Cryptic Epitope Expressed when β -Glycoprotein I Is Bound to a Suitable Surface. <i>Thrombosis and Haemostasis</i> , 1995 , 73, 029-034	7	90
25	IPO-V2: a prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 1994 , 23, 27-34	15.1	48
24	Antiphospholipid antibodies are not present in the membrane of gel-filtered platelets of patients with IgG anticardiolipin antibodies, lupus anticoagulant and thrombosis. <i>Blood Coagulation and Fibrinolysis</i> , 1993 , 4, 425-8	1	19
23	Reversal of excessive effect of regular anticoagulation. <i>Blood Coagulation and Fibrinolysis</i> , 1993 , 4, 739-741	4.1	48
22	Purification of anticardiolipin and lupus anticoagulant activities by using cardiolipin immobilized on agarose beads. <i>Thrombosis Research</i> , 1993 , 72, 423-30	8.2	17
21	Reversal of excessive effect of regular anticoagulation: low oral dose of phytonadione (vitamin K1) compared with warfarin discontinuation. <i>Blood Coagulation and Fibrinolysis</i> , 1993 , 4, 739-41	1	12
20	PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. <i>Journal of the American College of Cardiology</i> , 1992 , 20, 520-6	15.1	284

19	Renal artery thrombosis and hypertension in a 13 year old girl with antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 1990 , 49, 184-7	2.4	57
18	A brief contact of native whole blood with adenosine diphosphate (ADP) promotes the release of the contents of platelet alpha granules but not dense bodies and increases platelet retention to glass bead columns. <i>Folia Haematologica: Internationales Magazin Für Klinische Und Morphologische Blutkunde</i> , 1988 , 117, 252-254		1
17	The optimal therapeutic range for oral anticoagulant treatment as suggested by fibrinopeptide A (FpA) levels in patients with heart valve prostheses. <i>European Journal of Clinical Investigation</i> , 1989 , 19, 181-4	4.6	6
16	Immunological specificity and mechanism of action of IgG lupus anticoagulants. <i>Blood</i> , 1987 , 70, 69-76	2.2	188
15	Immunological specificity and mechanism of action of IgG lupus anticoagulants. <i>Blood</i> , 1987 , 70, 69-76	2.2	28
14	The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. <i>Blood</i> , 1986 , 68, 869-874	2.2	389
13	The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. <i>Blood</i> , 1986 , 68, 869-74	2.2	50
12	Adenosine diphosphate (ADP)-induced alpha-granules release from platelets of native whole blood is reduced by ticlopidine but not by aspirin or dipyridamole. <i>Thrombosis and Haemostasis</i> , 1986 , 56, 147-50		3
11	The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. <i>Blood</i> , 1986 , 68, 869-874	2.2	4
10	Adenosine Diphosphate (ADP)-Induced α -Granules Release from Platelets of Native Whole Blood Is Reduced by Ticlopidine but Not by Aspirin or Dipyridamole. <i>Thrombosis and Haemostasis</i> , 1986 , 56, 147-150		18
9	Do malfunctioning bioprosthetic heart valves represent a potential thrombogenic focus?. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1985 , 15, 337-44		
8	Beta-thromboglobulin (beta-TG) and platelet factor 4 (PF4) release by adenosine diphosphate (ADP) contact with native whole blood. <i>Thrombosis Research</i> , 1985 , 39, 645-50	8.2	5
7	Monitoring liver regeneration after right hepatectomy. <i>The Italian Journal of Surgical Sciences</i> , 1985 , 15, 75-7		3
6	Enhanced In Vitro Release of Platelet α Granules After Acute Myocardial Infarction (AMI). <i>Thrombosis and Haemostasis</i> , 1985 , 54, 544-546	7	1
5	The Evaluation of Fibrinogen Behavior in Hodgkin's Disease: Correlation with Clinical Stage. <i>Tumori</i> , 1983 , 69, 123-127	1.7	
4	Behavior of Antithrombin III, Determined as Protein Concentration and Biologic Activity, in Subjects with Neoplastic Disease. <i>Tumori</i> , 1982 , 68, 205-209	1.7	1
3	Abnormal migration of serum antithrombin III in patients on coumarin therapy by cross-immunoelectrophoresis. <i>British Journal of Haematology</i> , 1981 , 49, 490-2	4.5	2
2	Bidimensional Immunoelectrophoresis Abnormal Migration of Serum Antithrombin III in Coumarin-Treated Patients. <i>Thrombosis and Haemostasis</i> , 1981 , 46, 669-669	7	

- 1 Radioiodinated fibrinogen in the evaluation of patients with osteosarcoma. *European Journal of Cancer*, **1980**, 16, 261-5